Ascendis Pharma AS (ASND)
125.66
+0.38
(+0.31%)
USD |
NASDAQ |
Nov 04, 16:00
125.66
0.00 (0.00%)
After-Hours: 20:00
Ascendis Pharma Research and Development Expense (Annual): 447.61M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 447.61M |
| December 31, 2022 | 400.35M |
| December 31, 2021 | 350.06M |
| December 31, 2020 | 297.96M |
| December 31, 2019 | 214.52M |
| December 31, 2018 | 165.65M |
| Date | Value |
|---|---|
| December 31, 2017 | 112.79M |
| December 31, 2016 | 73.07M |
| December 31, 2015 | 44.97M |
| December 31, 2014 | 26.20M |
| December 31, 2013 | 16.88M |
| December 31, 2012 | 14.63M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
214.52M
Minimum
2019
447.61M
Maximum
2023
342.10M
Average
350.06M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Evaxion Biotech AS | 11.92M |
| Adaptimmune Therapeutics PLC | 126.51M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | 31.19M |
| Genfit SA | 50.57M |